Tradeoffs

After 20 years, Humira – the best selling drug of all time – is finally facing direct competition. Typically, once generic drugs arrive on a market they dominate sales and deliver big savings. But Humira’s competitors, known as biosimilars, aren’t like most other generics.This week, what makes this prescription drug showdown so unusual – and so important.Guest:Marta Wosińska, PhD, Visiting Fellow, Brookings InstitutionLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift. Hosted on Acast. See acast.com/privacy for more information.

A congressional ban on removing anyone from Medicaid will expire early next year. What will happen to people who lose their coverage, and how are states preparing for this unprecedented undertaking?Guests: Elizabeth Nash, Principle Policy Associate, State IssuesCindy Mann, Partner, Manatt Health Rachel Cohrs, Washington Correspondent, STATLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift.Follow us on Twitter.  Hosted on Acast. See acast.com/privacy for more information.

We've got a lot to share with you in 2023!We're looking into what might happen to the marketplace as Humira, the best selling prescription drug in history, goes generic; and profile a woman pioneering a new strategy to help people better manage their own health, a strategy that has insurance companies whispering.The FDA has approved another controversial Alzheimer’s drug, Medicare is gearing up to negotiate drug prices, millions of Americans could lose their Medicaid…and, of course, abortion. Tradeoffs is here to take you through the health care year ahead. We’ll explore the policies and programs, and we’ll introduce you to the people whose lives they shape.New episodes start 19 January, 2023!Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff.Support this type of journalism today, with a gift.Follow us on Twitter @tradeoffspod. Hosted on Acast. See acast.com/privacy for more information.

There’s a severe shortage of people to care for older Americans in their homes and nursing facilities. And it’s only expected to get worse. Could providing long-term care workers with new career pathways be part of the solution?Guests: Serena Maria, Manager of Care Teams, HomebridgeMark Burns, Executive Director, HomebridgeNatasha Bryant, Senior Director of Workforce Research and Strategy, LeadingAge LTSS Center at UMass Boston Jonathan Gruber, PhD, Ford Professor of Economics, MITLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift.Follow us on Twitter.  Hosted on Acast. See acast.com/privacy for more information.

California is in the early days of one of the most ambitious initiatives ever to address Medicaid patients’ social needs in hopes of improving their health. This week, we trace the origins, early results and challenges of “CalAIM.”Guests:Jacey Cooper, Director, California Medicaid ProgramBradley Gilbert, MD, MPP, Former Chief Medical Officer and CEO, Inland Empire Health PlanLacy McClellanDale StoutAnthony Wright, Executive Director, Health Access CaliforniaPaula Lantz, PhD, James B. Hudak Professor of Health Policy, University of Michigan Gerald R. Ford School of Public PolicyLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift.Follow us on Twitter.  Hosted on Acast. See acast.com/privacy for more information.

The Inflation Reduction Act gives Medicare historic new powers to control prescription drug prices. We go inside the government’s race to implement these new powers — and the pharmaceutical industry’s efforts to blunt their impact.Guests:Alice Valder Curran, JD, Partner, Hogan LovellsSean Dickson, JD, MPH, Director of Health Policy, West Health Policy CenterAmber Jessup, PhD, Chief Economist, Office of Inspector General, Department of Health and Human ServicesMark Newsom, Founder and Principal, Health EvaluationsLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift.Follow us on Twitter.  Hosted on Acast. See acast.com/privacy for more information.

Independent abortion funds have been flooded with donations since Roe v. Wade was overturned. How do these funds work and what role will they play in a post-Roe world?Guests:Brittany Mostiller, Leadership Development Coordinator, National Network of Abortion FundsGretchen Ely, PhD, MSW, Director of PhD Program, University of Tennessee College of Social WorkKim Floren, Director, Justice Through Empowerment NetworkErin Smith, Executive Director, Kentucky Justice Health NetworkRead a full transcript and dig deeper into our reporting here.Please take a couple of minutes to help us learn more about you by filling out our listener survey.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift. Hosted on Acast. See acast.com/privacy for more information.

The leader of a landmark abortion study shares what research and her own family experience suggest will happen to people who are denied abortions in a post-Roe world.Guests: Diana Foster Green, director of research at Advancing New Standards in Reproductive HealthRead a full transcript and dig deeper into the issues explored in today's episode on our website.Support this type of journalism today by making a donation.Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff.Follow us on Twitter. Hosted on Acast. See acast.com/privacy for more information.

Our annual look back at some of the best health care podcast episodes of the year with help from a few of our podcast host friends.Guests:Dr. Abdul El-Sayed, Policymaker in Residence, University of Michigan's Gerald R. Ford School of Public Policy and host of America DissectedKeris Myrick, Vice President of Partnerships, Inseparable and host of Unapologetically Black UnicornLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift, and have your donation tripled if you give before the end of 2022. Hosted on Acast. See acast.com/privacy for more information.

More than $50 billion in opioid settlement dollars from drugmakers, distributors and pharmacies is starting to flow to state and local governments and they need to figure out how to spend it. Guests: Dave Baker, Minnesota State Representative and chair of the state’s Opioid Epidemic Response Advisory Council Sara Whaley, Opioid Policy Researcher at Johns Hopkins Bloomberg School of Public Health @saraewhaleyLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift, and have your donation tripled if you give before the end of 2022. Hosted on Acast. See acast.com/privacy for more information.